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Angiotensin converting enzyme gene polymorphism and renal hemody.
namic function in early diabetes. An insertion/deletion (lID) of the human
angiotensin converting enzyme (ACE) gene is a major determinant of
circulating ACE levels. Recent studies suggest that the ACE lID polymor-
phism may influence the risk of developing nephropathy in patients with
insulin dependent diabetes mellitus (IDDM), although the mechanism
responsible for the effect is unknown. Since an early increase in glomerular
filtration rate (GFR) may also be a risk factor for the development of
diabetic nephropathy, we sought to determine if the ACE lID polymor-
phism influenced renal hemodynamic function in patients with IDDM.
Genomic DNA was obtained from 39 normotensive male and female
patients with uncomplicated IDDM (mean duration 3.4 years; range 1 to
6 years), and from 20 non diabetic control subjects. The ACE lID
polymorphism was determined using the polymerase chain reaction.
Subjects were divided into three groups based on their ACE genotype.
Values for GFR, renal plasma flow (ERPF), filtration fraction, and renal
vascular resistance were determined in both groups using classic inulin and
paraaminohippurate clearance techniques. Blood glucose was maintained
between 4 to 6 mmol/liter in the patients with IDDM using a modified
euglycemic clamp technique. Mean values for GFR were significantly
greater in patients homozygous for the I allele (143 7 mlIminIl.73 m2)
compared to patients homozygous for the D allele (121 3 mllmin/1.73
m2, P < 0.01), while the mean GFR values for the heterozygous patients
were intermediate. ERPF was also significantly greater in patients ho-
mozygous for the I allele (850 103 mllmin/1.73 m2) compared to patients
homozygous for the D allele (672 31 ml/min/1.73 m2, P < 0.04), while
there were no differences in the values for mean arterial pressure,
glycosylated hemoglobin, or albumin excretion rates amongst the groups.
There was no dominant effect of the ACE gene lID polymorphism in the
control group. These results suggest that: (1) the ACE gene lID polymor-
phism influences glomerular filtration and renal plasma flow rates in
patients with early uncomplicated IDDM; and (2) differences in renal
hemodynamic function do not appear to explain the protection against the
development of diabetic nephropathy offered by the I allele.
In 1990, Rigat and co-workers reported that a polymorphism of
the human angiotensin converting enzyme (ACE) gene, defined
by the insertion (I) or deletion (D) of 287 base pairs in intron 16,
accounted for approximately 47% of the phenotypie variance in
serum ACE levels in a population of 80 healthy individuals. Mean
values for serum ACE were greater in patients homozygous for
the D allele than in patients homozygous for the I allele, while
mean values were intermediate in heterozygotes. Therefore, it was
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concluded that ACE lID polymorphism was a major determinant
of circulating ACE levels [1]. Subsequently, Cambien et al showed
that patients homozygous for the D allele were at increased risk
for the development of myocardial infarction [2]. Nakai and
coworkers also found that the D allele conferred a risk for the
development of angina and myocardial infarction in a study of
Japanese patients [3].
More recently, a number of investigators have examined the
effect of the I/D polymorphism on the risk of developing nephrop-
athy in patients with insulin dependent diabetes mellitus (IDDM)
[4—8]. Marre and coworkers first reported a predominance of the
I allele among patients with IDDM without nephropathy [4],
while Doria, Warram and Krolewski found that the D allele
tended to he more frequent in a group of patients with IDDM and
nephropathy [51. Although the mechanism responsible for the
effect of the l/D polymorphism on the risk of developing nephrop-
athy is unclear, and not all the studies have demonstrated an
influence [6—8], it has been suggested that the association might
relate to an effect of the ACE I/D polymorphism on renal
hemodynamic function [4, 5].
Renal hemodynamic function is perturbed in clinical and
experimental insulin dependent diabetes. Early in its course, renal
vascular resistance (RVR) declines in patients with IDDM com-
pared to non-diabetic subjects and this reduction in RVR is
associated with increases in glomerular filtration rate (GFR),
renal plasma flow (ERPF) and filtration fraction (FF) [9, 10].
Animals with experimental diabetes also exhibit hyperfiltration,
and micropuncture studies have revealed that an increase in
glomerular capillary pressure accompanies the rise in GFR [11].
Although the mechanisms responsible for initiating and maintain-
ing diabetic renal hyperperfusion and hyperfiltration are not fully
understood, increases in pressures and flows in the renal circula-
tion have been implicated as major risk factors for the develop-
ment of diabetic glomerulopathy [12—14].
Accordingly, we sought to determine if the 1/D ACE polymor-
phism influenced renal hemodynamic function in patients with
early IDDM, in order to address the hypothesis that the I/D
polymorphism contributes to the risk of developing diabetic
glomerulopathy by altering renal hemodynamic function. To
examine this hypothesis, 39 subjects with early IDDM and 20
non-diabetic control subjects were investigated. An assay based on
the polymerase chain reaction (PCR) was used to identify the
ACE genotype, and classic inulin and paraaminohippurate (PAH)
clearance techniques were used to determine renal hemodynamic
function.
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Methods
Subjects
Males and females with diabetes were recruited for this study.
Their mean age was 28 1. They were all insulin dependent, and
were studied within six years of diagnosis (mean duration 3.4
years; range 1 to 6 years). They were otherwise healthy, normo-
tensive, and non-obese, on no medications except for insulin, and
without complications, including retinopathy, microalbuminuria,
and signs and symptoms of autonomic neuropathy. They were
subdivided on the basis of genotype, and thus three homogeneous
groups (DD, ID, H) were formed for this experiment. The study
was performed with the approval of the University of Toronto
Human Subjects Review Committee, and with the informed
written consent of each subject.
Twenty non-diabetic males and females were also recruited as a
comparison group. Their mean age was 26 2. They were all
normotensive, non-obese, and on no medications. For seven days
prior to the studies, all subjects were counselled by a research
dietitian to adhere to a diet that maintained their normal caloric
intake, and standardized their protein intake to 1 g/kglday, and
their the dietary sodium intake to approximately 150 mmol per
day. A 24-hour urine was obtained one day prior to the study to
determine urinary sodium excretion. Subjects with IDDM were
admitted to the Clinical Investigation Unit of the Toronto Hos-
pital the evening prior to the study day. An 18-gauge peripheral
venous cannula was inserted into an antccubital vein for infusions
of insulin and a 19-gauge sampling line was inserted in the
ipsilateral arm. Blood glucose was measured every hour (Accu-
check), and euglycemia (blood glucose 4.0 to 6.0 mmol/liter) was
maintained by minor variations in the insulin infusion [10, 15, 161.
Insulin was infused at an average rate of 0.9 0.01 units/hr during
the night prior to the study, and was continued throughout the
study.
On the day of the testing, the volunteer subjects reported to the
Renal Physiology Laboratory. All studies were conducted at 0830
hours, after an overnight fast, with the subjects lying supine in a
warm, quiet room.
Study protocol
Each patient voided and then drank 800 ml water in the first 45
minutes in order to induce a water diuresis. Two hundred
millilters of water were ingested in each hour of the protocol to
maintain an adequate urine output for collection of spontaneously
voided samples. A third venous catheter was inserted for infusion
of inulin and PAH. Hemodynamic parameters [mean arterial
pressure (MAP), heart rate] were recorded throughout the study.
In the subjects with IDDM, plasma glucose was measured every
30 minutes by the glucose oxidase method (Beckman Glucose
Analyzer II; Beckman Instruments Corp., Fullerton, CA, USA).
Euglycemia was maintained throughout the study by minor ad-
justments in the insulin infusion rate. In all subjects, renal
hemodynamics were measured using inulin and PAH clearance
techniques. After collecting blood for inulin blank, ACE gene
determination, insulin levels and glycosylated hemoglobin
(HbA1C), and urine for inulin blank, a priming infusion contain-
ing 25% inulin (60 mg/kg) and 20% PAH (8 mg/kg) was admin-
istered. Thereafter, inulin and PAH were infused continuously at
a rate calculated to maintain their respective plasma concentra-
tions constant at 20 and 1.5 mg/dl. After a 90- minute equilibra-
tion period, three timed urine collections of 20 minutes duration
each were then obtained by spontaneous voiding. Blood samples
collected for inulin and PAH determinations were immediately
centrifuged at 3000 rpm for 10 minutes at 4°C. Plasma was
separated, placed on ice, and then stored at —70°C before the
assay. Urine samples collected from subjects with IDDM for
measurement of inulin and PAH were promptly alkalinized by
addition to 4 ml urine of 23 jsl of 4 M NaOH to prevent formation
of an adduct between PAH and glucose [17]. Inulin concentra-
tions in plasma and urine were measured by a modified method of
Walser, Davidson, and Orloff [18] and PAH concentration, by a
spectrophotometric method according to Brun [19]. The mean of
the final two clearance periods represent GFR and ERPF,
expressed per 1.73 m2. FF represented the ratio of GFR to ERPF.
RBF was calculated by dividing the ERPF by (1 — hematocrit).
RVR was derived by dividing MAP by the RBF.
ACE genotype
The lID genotypes were defined according to the method of
Rigat et al [20]. The l/D polymorphisms were detected using PCR
with two specific primers (primer 1: 5'CTGGAGACCACTC-
CCATCCCTTTCT; primer 2: 5' GATGTGGCCATCACAT-
TCGTCAGAT) designed to amplify the polymorphic fragment
from human genomic DNA. The amplification was carried out
according to the specific PCR conditions published [20] using a
thermal cycler (Perkin Elmers 9600), and 5% DMSO was added
to prevent mistyping of the DD allele. The reaction products were
analyzed by agarose gel electrophoresis after ethidium bromide
staining. The presence of a single 190-hp fragment defined the
homozygous DD genotype and the presence of a single 490-bp
fragment defined the homozygous II genotype. The presence of
both fragments defined a heterozygous ID genotype.
Statistical analysis
Subjects were segregated into subgroups on the basis of ACE
genotypes. Results are presented as mean SEM and were
analyzed using analysis of variance (SAS). Differences between
means of subgroups were assessed using Tukey's Studentized
range test, to correct for multiple comparisons in subgroups of
differing sizes. Results were also analyzed non-parametrically
(SAS), examining the prevalence of each ACE gene subgroup
(Wilcoxin rank sum), in groups categorized by range of GFR (<
120 ml/min/1.73 m2, > 130 ml!min/I.73 m2, and intermediate).
Results
In the group with IDDM, 20 subjects displayed the DD
genotype, lithe ID genotype, and 8 the II genotype. As shown in
Table 1, there were no significant differences between the three
subgroups in age or duration of diabetes. Subgroups also had
similar values for MAP and HbAJC (normal = < 6%). Urinary
albumin excretion rate was within the normal range for all
subjects (normal = < 15 jsglmin), and no differences were
observed between subgroups. Urinary sodium excretion was
equivalent in all subgroups.
Significant differences in GFR, ERPF, and RBF existed be-
tween ACE genotype subgroups (Fig. 1). In comparison with the
DD subgroup, subjects homozygous for the I allele exhibited
significantly higher values for GFR (143 7 vs. 121 3
ml/min/1.73 m2, P = 0.008), ERPF (850 103 vs. 672 31
ml/min/1.73 m2, P = 0.04), and RBF (1464 174 vs. 1141 56
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Abbreviations are: M/F, male/female; HbA1C, glycosylated hemoglo-
bin; MAP, mean arterial pressure; AER, albumin excretion rate; BMI,
body mass index.
ml/min/1.73 m2, P = 0.04). Heterozygous subjects exhibited values
which were intermediate between the II and DD subgroups
(GFR = 126 3; ERPF = 657 37; RBF = 1103 67).
Although RVR appeared numerically decreased in the II sub-
group in comparison to the DD and ID subgroups (65 6 vs. 82
5 vs. 84 6 mm Hg/liter/mm), this value did not reach statistical
significance. Similarly, there was no significant difference in FF
between the subgroups, with the II subgroup result 0.18 0.01,
the DD result 0.19 0.007, and the ID result 0.2 0.01.
When analyzed non-parametrically, there was an excessive
predominance of the II genotype in subjects with GFR > 130
ml/min/1.73 m2 (P = 0.008).
There was no relationship between HbA1C and GFR, RPF,
RBF, FF, or RVR. Similarly, there were no relationships between
these renal parameters and age, duration of diabetes, or MAP.
In the non-diabetic control group, when segregated by ACE
genotype, 7 subjects displayed the DD polymorphism, 9 the ID,
and 4 the II. No significant differences existed between groups in
age, body mass index, or MAP. When analyzed by analysis of
variance, the GFR in the DD group was 117 15 ml/min/1.73 m2,
in the II group 120 29, and in the ID group 116 9 (P = NS).
Similarly, using a nonparametic analysis (SAS), there was no
excessive predominance of any haplotype when segregated by
range of GFR (P = NS).
Discussion
Early clinical and experimental IDDM is associated with an
increase in GFR [9, 10, 13], and micropuncture studies of diabetic
rats have shown that the increased GFR is a function of aug-
mented renal plasma flow rates and glomerular capillary pressure
[11, 12]. Since the mechanisms responsible for these changes in
renal hemodynamic function have not been fully elucidated, the
first aim of the current study was to determine if the recently
described ACE gene I/D polymorphism independently influenced
renal hemodynamic function in a group of patients with early
uncomplicated IDDM.
The rationale for proceeding with this aim was twofold. First,
several studies have suggested that the renin-angiotensin system is
perturbed in both experimental and clinical IDDM [15, 21—23].
Interventions ranging from ACE inhibition [24], rigorous glycemic
control [251, and protein restriction [26] all limit development of
diabetic glomerulopathy, possibly by influencing the renin-angio-
tensin system [27—29]. Second, recent studies indicate that the I/D
polymorphism of intron 16 in the human ACE gene is an
important determinant of circulating and tissue ACE levels [1, 30,
Table 1. Diabetic subjects
Parameter
Genotype
M/F
Age years
Duration of JDDM years
HbA1C %
MAP mm fig
AER pg/mm
Urine Na mmol/day
BMI kg/rn2
12/8
27 1
3.4 0.4
8.4 0.3
89 1
8.4 1.2
148 2
23 2
6/5
29 2
3.6 0.5
8.9 0.7
89 2
9.3 2.3
150 3
24 I
4/4
29 2
2.9 (1.6
8.4 0.4
89 2
8.8 2.5
154 4
23 1.5
31].
(N=2O) (N =11) (Ni! 8) The major finding of this study was that significant differencesin GFR and ERPF rates exist among patients with early uncom-
plicated IDDM when they are segregated on the basis of their
ACE genotype. Specifically, patients homozygous for the I allele
exhibited higher GFR and ERPF than the patients homozygous
for the D allele, while mean values were intermediate in the
heterozygous patients. Values for MAP were similar in all three
groups so that the differences in plasma flow rates reflected
changes in RVR. Mean values for RVR were numerically higher
in the patients homozygous for the D allele compared to the
patients homozygous for the I allele, although the difference did
not reach statistical significance.
Previous studies have shown that patients homozygous for the
D allele have higher circulating and tissue ACE levels, on average,
than heterozygotes or patients homozygous for the I allele [1, 30,
31]. Although classically renin is considered the rate-limiting step
for the generation of angiotensin II (Ang II), Morishita and
coworkers recently demonstrated that transfection of a human
ACE expression vector into vascular smooth muscle cells of the
carotid artery of rats led to an increase in the wall to lumen ratio.
The increase in the ratio was prevented by the angiotensin type I
receptor blocker, Dup 753. Therefore, a localized increase in
ACE activity can lead to increased Ang II generation in the wall
of the carotid artery [32]. A similar increase in intrarenal Ang II
activity, if present in patients homozygous for the D allele,
compared to patients homozygous for the I allele, might underlie
the differences in renal hemodynaniic function that we observed.
Of interest, Myers, Deen and Brenner showed that when Ang II
was infused into normal rats and the aorta was constricted to
prevent the myogenic response of the afferent arteriole to the Ang
Il-induced rise in arterial blood pressure, there were significant
declines in single nephron plasma flow rates and single nephron
glomerular filtration rates, despite increases in glomerular capil-
lary pressure [33]. Enhanced intrarenal Ang II production in the
IDDM patients homozygous for the D allele might therefore have
accounted for the lower mean values for GFR and ERPF that we
observed in this group, compared to the patients homozygous for
the I allele. In this regard it is also interesting to note that Allon,
Pasque and Rodriguez found that the ACE inhibitor, captopril,
increased GFR in normal human subjects, suggesting that intra-
renal ACE activity is indeed a determinant of intrarenal vascular
resistance [34]. However, further studies will be necessary to test
the hypothesis that the ACE l/D polymorphism influences intra-
renal ACE activity and intrarenal Ang II activity.
Doria and coworkers have reported that the ACE D allele
tended to be more common in patients with IDDM and evidence
of nephropathy, than in patients with IDDM without nephropa-
thy, although the increase in frequency did not attain statistical
significance [5]. Marre and coworkers found that the ACE I allele
was found significantly more commonly in IDDM patients who
did not have nephropathy than in IDDM patients with nephrop-
athy [4]. Taken together, these observations suggest that the lower
mean values for GFR that we observed in IDDM patients
homozygous for the D allele compared to those homozygous for
the I allele might be due to an increase in the incidence of diabetic
glomerulopathy in the DD group. However, none of the diabetic
patients studied had been insulin dependent for more than six
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years, and the mean duration of IDDM at the time of the study
was similar in each of the groups, ranging from 2.9 0.4 years in
the II group to 3.6 0.5 years in the ID group. Moreover, urinary
albumin excretion rates were determined in all of the patients, and
were similar in all groups, averaging less than 10 j.tg/min. The
combination of the short duration of IDDM prior to the study and
the similar values for both urinary albumin excretion rates and
mean arterial pressures suggest that the differences in GFR and
ERPF between the II and the DD groups were not due to
differences in underlying diabetic glomerular injury.
Viberti and coworkers have reported that normalization of
blood glucose levels reduces GFR in patients with IDDM [351, so
that the lower values for GFR in the DD group might have
reflected better glycemic control than in the II group during the
pre-study period. To address this concern, mean values for Hb
A1C were determined and found to be equivalent in each of the
groups of diabetic patients, suggesting that short-term differences
in glycemic control were not responsible for our observed differ-
ences in GFR and ERPF. To ensure that blood glucose levels
were similar during the measurement of GFR, all of the physio-
logical studies were performed while the patients were euglycemic
during a modified glucose clamp.
Potential confounding variables also included differences in
sodium and protein intake amongst the groups. For example,
Bank and colleagues [36] have reported that sodium restriction
normalizes hyperfiltration in rats with experimental type I diabe-
tes, and Zatz and coworkers have shown that restriction in dietary
protein intake also limits hyperfiltration in experimental disease
[12]. To control for the influence of these factors on our measure-
ment of GFR and ERPF, patients were counselled by a research
dietitian to adhere to a 150 mmol sodium diet containing 1
g/kg/day protein. As expected, we found that the mean sodium
excretion rates were similar in the three groups, but we did not
determine urea excretion rates prior to the study. Therefore, we
cannot confirm that all subjects adhered to the dietary recommen-
dation for protein intake. Even though each of the patients was
studied in the post-absorptive state after an overnight fast, we
Fig. 1. (A) Glomerular filtration rate (GFR), (B)
filtration fraction (FF), (C) renal blood flow
(RBF), and (D) renal vascular resistance (RVR)
in subjects with IDDM, segregated on the basis of
ACE genotype. Symbols are: () DD; () ID;(• 11). *p < 0.05 compared to DD and ID
subgroups; P < 0.01 compared to DD
subgroup.
cannot rule out the influence of differences in protein intake
among the groups prior to admission, although this should have
been minimal, considering that the protein-induced rise in GFR is
maximal four and five hours after ingestion [371.
The second aim of the current study was to determine if there
was a hemodynamic basis for the reports suggesting that the ACE
lID polymorphism influenced the development of nephropathy in
patients with IDDM [4—8]. The rationale for this aim was that
studies by Mogensen [13] and Rudberg, Persson and Dahlquist
[14] have demonstrated that diabetes-induced hyperfiltration is
also a risk factor for the subsequent development of nephropathy.
We found that we could not reconcile these two risk factors, at
least at the level of whole kidney function. The I allele, putatively
associated with reduced risk of diabetic nephropathy in some [4,
5] but not all studies [6—8], was associated with the highest mean
values for GFR and ERPF, while the converse was found for the
D allele. Since the hyperfiltration state is well-established as a risk
factor for the eventual development of nephropathy in diabetic
populations [12—14], this finding is difficult to interpret.
Our failure to establish that differences in renal hemodynamic
function might account for the reported effect of the ACE lID
polymorphism on the development of diabetic nephropathy does
not preclude a role for this locus in diabetic glomerular injury.
The I allele could still confer protection against the development
of nephropathy in IDDM by altering intrarenal hemodynamic
function so that glomerular capillary pressure is normalized, an
effect that we would not have been able to measure by determin-
ing whole kidney GFR and ERPF. Since Ang II can directly
influence vascular smooth muscle cell growth and extracellular
matrix protein synthesis [38], the I allele also might confer
protection on a non-hemodynamic basis by limiting the intrarenal
generation of Ang II, although this hypothesis remains specula-
tive.
The results gleaned from the non-diabetic control subjects
deserve comment. It is interesting to note that there did not
appear to be a dominant effect of the ACE l/D genotype on GFR
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in this group, although admittedly, the numbers of those homozy-
gous for the 1 allele were small. Apparently, the diabetic milieu is
required for the II genotype to impact on renal hemodynamic
function. In fact, it has been shown that mild short-term hyper-
glycemia may activate the renin-angiotensin system and increase
renal vascular resistance in early IDDM [27].The possibility exists
that the diabetic DD subgroup exhibited augmented intrarenal
Ang II activity, resulting in a normalization of GFR and RBF.
In summary, the current study establishes that an [IDpolymor-
phism of intron 16 in the human ACE gene influences GFR and
ERPF in patients with early uncomplicated IDDM. Patients
homozygous for the I allele exhibit higher mean values for GFR
and ERPF compared to patients homozygous for the D allele.
Further studies will be necessary to determine the mechanism(s)
responsible for this effect.
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